安络化纤丸联合恩替卡韦治疗乙肝肝硬化的效果及对肝功能的影响
2020-12-23李朝晖张晓龙郭彦清王晓玲沈丽贤康艳艳房冲冲齐欣慈
李朝晖 张晓龙 郭彦清 王晓玲 沈丽贤 康艳艳 房冲冲 齐欣慈



[摘要] 目的 探讨安络化纤丸联合恩替卡韦治疗乙肝肝硬化的临床效果。 方法 选取2017年6月—2018年6月于河北中医肝病医院收治的乙肝肝硬化患者68例,依据随机数字表法分为两组,各34例。对照组接受恩替卡韦治疗,观察组接受安络化纤丸联合恩替卡韦治疗,疗程均持续1年。比较两组治疗后的乙肝病毒核酸(HBV-DNA)和乙型肝炎E抗原(HBeAg)转阴率、Child-Pugh评分及肝功能指标、血清肝纤维化指标、肝脾影像学指标及不良反应。 结果 观察组治疗后的HBV-DNA和HBeAg转阴率高于对照组,差异有统计学意义(P < 0.05)。观察组治疗后的Child-Pugh评分、白蛋白及总胆红素水平均低于对照组,谷丙转氨酶水平高于对照组,差异有统计学意义(P < 0.05)。观察组治疗后的血清透明质酸酶、人层粘连蛋白及Ⅲ型前胶原水平均低于对照组,差异有统计学意义(P < 0.05)。观察组的肝脾影像学门静脉主干直径缩小、脾长缩小及脾静脉缩小比例均高于对照组,差异有统计学意义(P < 0.05)。所有患者治疗期间均未出现不良反应。 结论 安络化纤丸联合恩替卡韦治疗乙肝肝硬化的效果确切,能明显改善患者肝功能,并解除肝纤相关指标恶化趋势,是一种值得推广的疗法。
[关键词] 安络化纤丸;恩替卡韦;乙肝肝硬化;Child-Pugh评分;肝功能指标;肝纤维化指标;肝脾影像学
[中图分类号] R575 [文献标识码] A [文章編号] 1673-7210(2020)10(a)-0151-04
Effect of Anluohuaxian Pills combined with Entecavir in the treatment of hepatitis B cirrhosis and its influence on liver function
LI Zhaohui1 ZHANG Xiaolong2 GUO Yanqing3 WANG Xiaoling3 SHEN Lixian3 KANG Yanyan1 FANG Chongchong1 QI Xinci1
1.Ward 2, Hebei Traditional Chinese Medicine and Liver Disease Hospital, Hebei Province, Shijiazhuang 050800, China; 2.Department of Ultrasound, Hebei Traditional Chinese Medicine and Liver Disease Hospital, Hebei Province, Shijiazhuang 050800, China; 3.Ward 1, Hebei Traditional Chinese Medicine and Liver Disease Hospital, Hebei Province, Shijiazhuang 050800, China
[Abstract] Objective To explore clinical effect of Anluohuaxian Pills combined with Entecavir in the treatment of hepatitis B cirrhosis. Methods Sixty-eight patients with hepatitis B cirrhosis admitted to Hebei Traditional Chinese Medicine and Liver Disease Hospital from June 2017 to June 2018 were selected and divided into two groups according to random number table method, 34 cases in each group. Control group received Entecavir treatment, observation group received Anluohuaxian Pills combined with Entecavir treatment, the course of treatment lasted for one year. The negative conversion rate of HBV-DNA and HBeAg, Child-Pugh score and liver function index, serum liver fibrosis index, liver spleen imaging index and adverse reactions were compared between two groups. Results The negative conversion rates of HBV-DNA and HBeAg in observation group after treatment were higher than those in control group (P < 0.05). After treatment, Child-Pugh score, albumin and total bilirubin levels of observation group were lower than those of control group, and alanine aminotransferase level of observation group was higher than that of control group, the differences were statistically significant (P < 0.05). After treatment, the serum levels of hyaluronic acid, human laminin and procollagen type Ⅲ in observation group were lower than those in control group (P < 0.05). The diameter of portal vein trunk, the length of spleen and the proportion of splenic vein in observation group were significantly higher than those in control group (P < 0.05). No adverse reactions occurred during the treatment. Conclusion Anluohuaxian Pills combined with Entecavir in the treatment of hepatitis B cirrhosis has exact effect, it can significantly improve the liver function of patients, and relieve the deterioration trend of liver fiber related indicators, it is a kind of therapy worthy of promotion.
[Key words] Anluohuaxian Pills; Entecavir; Hepatitis B cirrhosis; Child-Pugh score; Liver function index; Liver fibrosis index; Liver and spleen imaging
肝硬化是一种临床中常见的慢性进行性肝病,其发病机制为一种或多种病因长期反复作用而造成的弥漫性肝损伤,在我国,肝硬化主要由肝炎转化而成,同时存在部分酒精性肝硬化和血吸虫性肝硬化[1-2]。在肝硬化早期中,受肝脏自身代偿作用的影响,发病特征并不显著,患者往往重视不足,但病情慢慢进展后,肝功能的一系列损害症状将大量出现,伴有一定的多系统损害,甚至出现消化道出血、肝性脑病以及继发感染等病情,严重威胁患者的生命安全[3]。本研究主要探讨安络化纤丸联合恩替卡韦治疗乙肝肝硬化的临床效果,现报道如下:
1 资料与方法
1.1 一般资料
选取2017年6月—2018年6月于河北中医肝病医院收治的乙肝肝硬化患者68例,依据随机数字表法分为两组,各34例。……
